Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53%) or low-dose total body irradiation (24%). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II-IV) and transplant-related mortality were significantly decreased (P ¼ 0.01 and Po10
Introduction
In patients with an available HLA identical sibling or unrelated donor, allogeneic haematopoietic stem cell transplantation (HSCT) for the treatment of acute myeloblastic leukaemia (AML) has, for decades, remained limited by patient age and physical condition. Indeed, the best results in terms of leukaemia-free survival (LFS) have essentially concerned younger patients. In patients over 50 years of age, HSCT has resulted in an unacceptable transplantation-related mortality (TRM) both due to the toxicity of the myeloablative (MA) regimen used as conditioning and the high incidence and severity of graft-versushost disease (GVHD). 1 Following studies in animal models, a new modality 'non-MA transplant or reduced intensity conditioning (RIC) regimen' has been developed [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] for older patients and patients with high risk of TRM, with the argument that a less intense preparative regimen would produce less organ damage, and still enable engraftment and occurrence of graft-versus-tumour effect. In the past 6 years, this approach has proved feasible and the induction of graft-versus-tumour effect has indeed generated a high rate of responses. It remains, however, unclear, whether the reduction in antitumour activity secondary to the decrease in intensity of the preparative regimen is compensated by the graft-versustumour effect, which in this approach is the key antitumour tool. 13 There has recently been a trend to use RIC even in patients who, a few years ago, would have been candidates for a conventional allogeneic HSCT. However, results of RIC reported have usually mixed various diseases 14 at different stages and the follow-up has remained short. Only recently a specific analysis of RIC and conventional transplants in patients with a single haematological malignancy, that is, multiple myeloma, has been reported by the European Blood and Marrow Transplant (EBMT) group. 15 In a retrospective analysis of 95 patients with AML analysed through a donor vs no donor genetic randomization, RIC transplant has been shown to be superior to chemotherapy, 16 but there has so far been no specific comparison of RIC to conventional transplants. 17 In order to compare mainly TRM and other outcomes, we analysed retrospectively the data on HLA identical sibling HSCT using RIC, and compared the outcome with HLA identical sibling HSCT using conventional MA transplants in adult patients over 50 years of age with AML reported to EBMT registry.
Materials and methods

Data collection
Data of HLA identical HSCT recipients older than 50 years receiving either a reduced intensity regimen or a conventional conditioning regimen were provided by the Acute Leukemia Working Party (ALWP) of the EBMT group. EBMT registry is a voluntary working group of more than 450 transplant centres, participants of which are required once a year to report all consecutive haematopoietic stem cell transplantations and follow-up.
Criteria of selection
The study included patients receiving HLA identical sibling HSCT who (1) were aged X50 years at time of transplant; (2) had de novo acute myeloid leukaemia; (3) were transplanted between 1 January 1997 and 31 December 2003; (4) had received a reduced intensity regimen defined as the use of fludarabine associated with low-dose total body irradiation (TBI) (o3 Gy), or busulphan (total dose p8 mg/kg), or other non-MA drugs; (5) had received a MA-based preparative regimen with TBIX10 or busuphfan (48 mg/kg) associated with other drugs; (6) were patients whose clinical data on outcomes were adequate.
All patients receiving previous autologous transplantation were excluded from this analysis.
A total of 315 RIC and 407 MA HSCT recipients from 182 transplant centres met these eligibility criteria.
Patients
The registry contained information on a total of 722 patients of whom 407 received an MA and 315 RIC. The patient-, diseaseand transplant-related factors and differences between the two groups of patients are given in Table 1 . Interestingly, the majority of patients was transplanted in CR1 (245 MA and 171 RIC). RIC patients were older (median 57 vs 54 years) -as were their donors (57 vs 52 years) -and more frequently male (61 vs 51%). They were also transplanted more recently (median year 2001 vs 2000). As a source of stem cells, peripheral blood was used in the majority for both transplant modalities, but was more frequently used for RIC (90 vs 69%). Regarding GVHD prophylaxis, RIC patients more often received cyclosporin A alone without methotrexate or a combination of cyclosporin A with mycophenolate mofetil (MMF). There was no other detectable difference: in particular, the FAB classification and the cytogenetics (in the populations where the information was available) were evenly split in the overall population and when stratifying by status at transplant.
The follow-up was 13 months (1-84) for the patients who received an MA regimen and 14 months (1-67) for those who received an RIC.
Statistical analysis
Patient-, disease-, and transplant-related variables of both groups were compared, using the w 2 statistic for categorical and the Mann-Whitney test for continuous variables. Variables considered were recipient age and sex; disease characteristics (FAB classification, cytogenetics, white blood count at the time of diagnosis); donor characteristics (age, sex); disease status at transplant (CR1, CR2 or more advanced disease); transplant characteristics including year of transplant and GVHD prophylaxis. Factors differing in distribution between the two groups with a P-value less than 0.10 and factors known to influence outcomes (such as status at transplant) were included in the final models. In order to test for a centre effect, we introduced a random effect or frailty for each centre into the model. 18, 19 Cumulative incidence curves were used in a competing risks setting, death being treated as a competing event to calculate probabilities of chronic GVHD (cGVHD), TRM and relapse. 20 Probabilities of survival and LFS were calculated using the Kaplan-Meier estimate; the log-rank test was used for univariate comparisons. Associations of graft type with outcomes were evaluated in multivariate analyses, using Cox proportional hazards for LFS and survival, logistic regression for acute GVHD (aGVHD), and proportional subdistribution hazard regression model of Fine and Gray 21 for other outcomes. All P-values are two-sided with type I error rate fixed at 0.05. Statistical analyses were performed with SPSS (Inc., Chicago) and Splus (MathSoft, Inc, Seattle) software packages. Table 2 indicates the unadjusted outcomes post-transplant according to disease status at transplants and according to MA or RIC.
Results
Graft-versus-host disease
aGVHD grade II-IV was observed in 114 patients receiving an MA transplant (63 patients with grade II, 28 with grade III and 23 with grade IV) and in 64 patients receiving an RIC transplant (38 patients with grade II, 14 with grade III and 12 with grade IV). Incidence of grade II-IV aGVHD was significantly lower after RIC: 22% compared to 31% after MA HSCT (P ¼ 0.003) but not grade III-IV (8 vs 12%, respectively) (P ¼ 0.12) ( Table 2) .
In a multivariate analysis, after statistical adjustment for relevant risk factors, risk of grade II-IV aGVHD was significantly lower after RIC than after MA transplant. The relative risk of grade II-IV aGVHD with RIC vs MA was 0.60 (95% CI ¼ 0.4-0.88, P ¼ 0.01). Other variables associated with lower aGVHD risk are listed in Table 3 . Multivariate analysis for grade III-IV Comparative outcome of RIC and MA regimen M Aoudjhane et al aGVHD was not performed due to the small number of events observed in both groups. The 2-year cumulative incidences of cGVHD were 48% after RIC compared with 56% after MA (P ¼ 0.64). In multivariate analysis, the risk of chronic GVHD was lower following RIC (RR ¼ 0.69; 95% CI ¼ 0.51-0.94, P ¼ 0.02).
Transplantation-related mortality
In univariate analysis, there was higher TRM after MA than after RIC regimen in patients transplanted in CR1, CR2 and advanced phase of the disease (Table 2 ). Cumulative incidence of TRM at 2 years for all patients was 32% after MA transplant compared to 18% after RIC transplant (Po0.001, Figure 1a) . In a multivariate analysis, the risk of mortality was statistically significantly higher for patients receiving an MA transplantation than for those receiving an RIC transplantation (Table 3) .
Relapse
In univariate analysis, not adjusted for differences between the two groups, the cumulative incidence of relapse was higher after RIC transplant: 41% compared to 24% after MA transplant (Po0.0001) (Figure 1b ). According to the disease status at transplant, relapse was also statistically significantly higher after RIC in patients transplanted in remission (CR1 or CR2) than in patients receiving an MA transplant (Table 2) . For those patients transplanted in the advanced phase of the disease, there was a trend for higher relapse rate also in RIC recipients (P ¼ 0.06). In a multivariate analysis, after adjustment for risk factors, relapse was increased in RIC recipients compared to those receiving an MA transplant. Other covariable associated with relapse incidence was the advanced phase of the disease at transplant (Table 3) .
Overall survival and LFS
Unadjusted 2-year probability of LFS and overall survival (OS) were 40 and 47%, (Figure 1c ) and 44 and 46% (Figure 1d ), in the RIC and MA cohorts, respectively. Table 2 lists results of unadjusted 2-year OS and LFS probability in each transplant cohort according to diagnosis and status of the disease at transplant. There was no significant difference for LFS and OS for patients receiving either MA or RIC HSCT whatever the status of the disease at transplant ( Table 2) . Results of multivariate analysis comparing LFS and OS after RIC and MA transplants are shown in Table 3 . Similarly to the univariate analysis, there was no significant difference in OS or LFS between both groups.
Causes of death
A total of 157 MA recipients and 137 RIC recipients died. Persistent or recurrent leukaemia caused 69 (44%) deaths in the MA group and 86 (64%) in RIC recipients. Table 4 lists causes of death in both groups. Of note, in the RIC group, there were Deaths related to toxicity other than GVHD were more common in MA recipients.
Discussion
This retrospective study concerns a large series of patients older than 50 years of age and transplanted for AML with an HLA identical sibling, following either an MA or an RIC regimen. It shows that following RIC, the TRM was lower than after a conventional transplant and the relapse incidence was higher. The reduction in TRM after RIC was expected since RIC was originally designed precisely in an effort to reduce TRM; indeed, recent studies comparing TRM in RIC and MA have further documented this reduction in non-GVHD toxicity 22, 23 : as a particular example, RIC patients conditioned with 2 Gy TBI have a lower reduction in 1-s forced expiratory volume (FEV1), forced vital capacity, total lung capacity, residual volume and carbon monoxide diffusion capacity than MA patients receiving TBI at 10 Gy. 24 GVHD is the other major component of TRM in HSCT and at the same time is associated with GVL effect: following allogeneic transplants using standard preparative regimen, the overall incidence of aGVHD grade II-IV is around 40% and the incidence of cGVHD around 60%, but it is known to be increased in older patients, where it contributes to poorer outcome. 1 The International Bone Marrow Transplant Registry (IBMTR) has shown 15 years ago that the relapse incidence was reduced in patients with aGVHD and/or cGVHD. 25 A study from EBMT has further indicated that the highest LFS after allogeneic bone marrow transplantation was seen in patients with grade I aGVHD. 26 Less is known on the incidence and severity of GVHD and the GVL effect following RIC in which the distinction between aGVHD and cGVHD is often more difficult with late onset (after 100 days) occurring aGVHD. 27 In this regard, using a specific definition, the Seattle team analysed retrospectively 171 consecutive patients, who had related or unrelated RIC HCT, for various haematologic malignancies for the development of serious aGVHD or cGVHD. 28 A total of 43 (25%) patients had serious GVHD, of whom 20 had grade III-IV aGVHD, and 30 had extensive chronic GVHD. To this were added seven patients with grade III aGVHD and 84 with extensive cGVHD that did not meet criteria for serious GVHD, indicating in the end an incidence of aGVHD IIIFIV, of 16%, and a very high incidence of chronic extensive GVHD, of 72%. In another study from the same team, 29 of a total of 221 patients with various haematological malignancies receiving an RIC, grade II-IV aGVHD had no significant impact on the risk of relapse or progression but was associated with an increased risk of nonrelapse mortality and a decreased probability of progression-free survival (PFS). Conversely, extensive cGVHD was associated with decreased risk of relapse or progression and increased probability of PFS. In this context, it is of interest in Comparative outcome of RIC and MA regimen M Aoudjhane et al our study, which is restricted to AML and genoidentical transplants in patients older than 50 years of age, to note that the incidence of aGVHD and cGVHD was lower following RIC than MA HSCT. Our finding on the lower incidence of grade II-IV aGVHD and cGVHD confirms the previous report by MD Anderson 30 on 137 transplanted patients where the actuarial rate of grade II-IV aGVHD was significantly higher in patients receiving MA regimens (36%) than in the RIC group (12%). In this report also, the cumulative incidence of cGVHD was higher in the ablative group (40%) than in the RIC group (14%). Unfortunately, due to the small number of patients presenting grade III-IV in both groups, a multivariate analysis was not possible to confirm the no statistical difference observed in the unadjusted univariate analysis for grade III-IV GVHD. However, GVHD remained the major cause of nonleukemic death after RIC probably because the other causes of death were considerably reduced (such as infections, liver VOD, interstitial pneumonitis).
The literature on RIC is considerable but specific studies of RIC on AML are limited: 31 previous retrospective reports on RIC for any given haematological malignancy, 32, 33 and most of all for AML, have usually concerned small series of patients from single institutions. Most retrospective studies, in fact have pooled various diseases. In a series of 36 patients from 55 to 66 years of age receiving an RIC transplant from an unrelated donor for various haematological malignancies, Shimoni et al 34 have reported a disease-free survival (DFS) of 43% at 1 year with an incidence of aGVHD grade II-IV and cGVHD of 31 and 45% with somewhat better outcome in patients with myeloid malignancies. They concluded that unrelated donor SCT is feasible in elderly patients, with outcomes that are similar to younger patients. The Boston team has compared 71 patients over 50 years of age receiving a non-MA transplant with 81 patients over 50 years of age who received an MA transplant during the period from 1997 to 2002. They concluded in similar outcome, with more relapses in RIC and lower TRM, but the patient population was very heterogeneous with various haematological malignancies (AML, ALL, myelodysplastic syndromes, CLL, myelomas, lymphomas and other). In this study, only 34 AML patients were transplanted, 21 with RIC and 13 with a conventional transplant. Moreover, this study also included related and unrelated transplants.
The value of RIC in AML therefore is unclear and yet, several teams have already taken the step at the institution policy level, to use RIC rather than MA transplants in patients over 50 years of age and, further, some have even proposed this scheme to younger patients and in first complete remission. Such a policy may at the moment be premature in view of the paucity of data and the still short follow-up. There has so far been no randomized study addressing the question of the comparison of RIC with MA transplants, although some are being planned.
The ALWP of the EBMT registry, because it contained information on a total of 721 patients with AML older than 50 years of age given an HLA identical sibling HSCT, was felt to be an interesting tool to approach two major questions; that is, first the outcome of older patients with AML receiving an RIC and second, its value as compared with MA HSCT. The present study shows that patients receiving an RIC had, at 2 years, a DFS of 4073% and an OS of 4773%, which is not different from the figures of 4473 and 4673%, respectively, following an MA HSCT. This was achieved despite a significant increase in relapse incidence with RIC but thanks to a significant decrease in TRM. Interestingly, these findings are reminiscent of the retrospective studies from EBMT, a decade ago, which compared conventional allogeneic stem cell transplantation with autologous stem cell transplantation and similarly showed for the latter a significant increase in relapse incidence counterbalanced by a significant decrease in TRM. 35 EBMT studies in progress are presently comparing RIC to autologous HSCT in elderly patients with AML.
The present study suffers from the usual limitations of retrospective and multicentre studies despite the fact that the two patient populations were similar in several characteristics, and patients receiving an RIC were older and were transplanted more recently. RIC is still an emergent transplant modality and not all centres perform both transplant modalities; 154 patients who received a conventional transplant were reported from 59 centres performing only conventional transplants; 104 patients who received an RIC were reported from 47 centres performing only RIC and 464 patients were reported from 76 centres performing both modalities. In these centres, the choice of the modality, in the absence of randomization, has probably relied on the patient performance status and physiological age, RIC being proposed to the more fragile patients in addition to the older as indicated above. By taking into account the centre effect 36 with the frailty model we, of course, try to erase some but not all the potential biases.
Finally, it is of interest that The Chronic Leukaemia Working Party of EBMT has recently reported results of a study similar to ours, but concerning patients with multiple myeloma; 15 the results were strikingly similar to ours, namely more relapses with RIC but lower TRM, in the end leading to similar DFS and OS following both transplant modalities.
In conclusion, this analysis shows that RIC in patients with AML older than 50 years of age is feasible and that in comparison with conventional transplants, it is associated with more relapses but less transplant toxicity. Since LFS and OS were not statistically different with the two modalities, albeit with a short follow-up, a randomized study in this high-risk population seems warranted. 
